drugset / Trial / NCT06932068
Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is single - arm study to explore the safety and efficacy of iparomlimab and tuvonralimab (QL1706) combined with chemotherapy for treating her2-negative, low PD-L1 expressing, unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma
Timeline
- Start
- 2025-03-26
- Primary completion
- 2026-10-31
- Completion
- 2027-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iparomlimab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Tuvonralimab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Background | Capectitabine | Unknown | 1000 mg/m2 | Oral |
| Background | Oxallplation | Unknown | 130 mg/m2 | Intravenous |